Amphastar Pharmaceuticals
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company.[2] It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.[3]
| Type | Public |
|---|---|
| Headquarters | Rancho Cucamonga, California, United States |
Key people |
|
| Revenue |  US$ 437.8 million (2021) |
| US$ 71.7 million (2021) | |
| US$ 62.1 million (2021) | |
| Total assets | US$ 671.5 million (2021) |
| Total equity |  US$ 445.5 million (2021) |
Number of employees | 1,761 |
| Website | Amphastar.com |
| Footnotes / references [1] | |
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic.[4] In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.[4]
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.[5]
See also
References
- "U.S. SEC: Form 10-K, Amphstar Pharmaceuticals, Inc". U.S. Securities and Exchange Commission. Retrieved March 16, 2022.
- "Amphastar Pharmaceuticals, Inc. (AMPH)". NASDAQ.com. NASDAQ OMX Group. Retrieved 3 January 2016.
- "Profile:Amphastar Pharmaceuticals Inc (AMPH.O)". Reuters.
- Arsalan, Arif (February 21, 2017). "After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar's intranasal version". Endpoints.
- Tyler, Eleanor (March 21, 2018). "Amphastar Patent Win Boosts Momenta, Sandoz Antitrust Case". Bloomberg. Retrieved March 24, 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.